Oncternal Therapeutics 관리
관리 기준 확인 3/4
Oncternal Therapeutics CEO는 Jim Breitmeyer, Jun2019 에 임명되었습니다 의 임기는 5.42 년입니다. 총 연간 보상은 $ 1.62M, 37.5% 로 구성됩니다. 37.5% 급여 및 62.5% 보너스(회사 주식 및 옵션 포함). 는 $ 38.03K 가치에 해당하는 회사 주식의 1.11% 직접 소유합니다. 38.03K. 경영진과 이사회의 평균 재임 기간은 각각 3.8 년과 5.4 년입니다.
주요 정보
Jim Breitmeyer
최고 경영자
US$1.6m
총 보상
| CEO 급여 비율 | 37.5% |
| CEO 임기 | 5.4yrs |
| CEO 소유권 | 1.1% |
| 경영진 평균 재임 기간 | 3.8yrs |
| 이사회 평균 재임 기간 | 5.4yrs |
최근 관리 업데이트
Recent updates
We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation
Jun 14
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?
Mar 03Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Nov 06Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely
Jul 12We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Jan 12FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy
Oct 03Oncternal Therapeutics begins phase 3 study of zilovertamab
Sep 27Oncternal Therapeutics: Selling For Under Cash Value
Sep 02Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M
Aug 09Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Aug 07Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study
Jul 14Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve
Jun 07We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Apr 12Oncternal Therapeutics: Trading Near Cash With Impressive Results
Jan 04Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans
Nov 09Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company
Oct 10Oncternal: Solid Data In 2 Cancers With High Unmet Need
Jun 17We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth
May 05Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?
Mar 01CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$35m |
| Jun 30 2024 | n/a | n/a | -US$36m |
| Mar 31 2024 | n/a | n/a | -US$36m |
| Dec 31 2023 | US$2m | US$609k | -US$39m |
| Sep 30 2023 | n/a | n/a | -US$42m |
| Jun 30 2023 | n/a | n/a | -US$43m |
| Mar 31 2023 | n/a | n/a | -US$46m |
| Dec 31 2022 | US$2m | US$580k | -US$44m |
| Sep 30 2022 | n/a | n/a | -US$41m |
| Jun 30 2022 | n/a | n/a | -US$39m |
| Mar 31 2022 | n/a | n/a | -US$35m |
| Dec 31 2021 | US$5m | US$557k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$26m |
| Jun 30 2021 | n/a | n/a | -US$21m |
| Mar 31 2021 | n/a | n/a | -US$18m |
| Dec 31 2020 | US$780k | US$530k | -US$17m |
| Sep 30 2020 | n/a | n/a | -US$19m |
| Jun 30 2020 | n/a | n/a | -US$19m |
| Mar 31 2020 | n/a | n/a | -US$37m |
| Dec 31 2019 | US$1m | US$502k | -US$34m |
| Sep 30 2019 | n/a | n/a | -US$31m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$7m |
| Dec 31 2018 | US$518k | US$426k | -US$7m |
보상 대 시장: Jim 의 총 보상 ($USD 1.62M )은 US 시장( $USD 650.80K ).
보상과 수익: Jim 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Jim Breitmeyer (70 yo)
5.4yrs
테뉴어
US$1,623,074
보상
Dr. James B. Breitmeyer, also known as Jim, M.D., Ph D., served as Director of Otonomy, Inc. since June 20, 2018 until February 2023. He serves as Director of Rebalance Health, Inc. He serves as the Chief...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 5.4yrs | US$1.62m | 1.11% $ 38.0k | |
| CFO & Treasurer | 5.4yrs | US$847.91k | 0.25% $ 8.5k | |
| Chief Technical & Scientific Officer | 3.8yrs | 데이터 없음 | 0.074% $ 2.6k | |
| General Counsel & Secretary | 3.6yrs | 데이터 없음 | 0.14% $ 4.9k | |
| Senior Vice President of Corporate Development | 3.3yrs | 데이터 없음 | 데이터 없음 |
3.8yrs
평균 재임 기간
55.5yo
평균 연령
경험이 풍부한 관리: ONCT 의 관리팀은 경험 ( 3.8 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 5.4yrs | US$1.62m | 1.11% $ 38.0k | |
| Independent Director | 18.5yrs | US$59.80k | 0.12% $ 4.2k | |
| Independent Director | 5.4yrs | US$67.50k | 0.017% $ 579.9 | |
| Independent Director | 5.4yrs | US$67.00k | 0.044% $ 1.5k | |
| Independent Chairman of the Board | 5.4yrs | US$103.82k | 0.024% $ 828.1 | |
| Independent Director | 3.8yrs | US$61.32k | 0.00017% $ 5.8 | |
| Scientific Advisor | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 5.4yrs | US$59.00k | 0.025% $ 850.4 | |
| Non-Independent Director | 5.4yrs | US$55.00k | 0.34% $ 11.6k | |
| Cell Therapy Scientific Advisory Board Member | 3yrs | 데이터 없음 | 데이터 없음 | |
| Prostate Cancer & Cell Therapy Scientific Advisory Board Member | 1.8yrs | US$941.21k | 0.062% $ 2.1k | |
| Cell Therapy Scientific Advisory Board Member | 3yrs | 데이터 없음 | 데이터 없음 |
5.4yrs
평균 재임 기간
70yo
평균 연령
경험이 풍부한 이사회: ONCT 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.